3/18
08:31 am
vnrx
Volition Reports Breakthrough in Liquid Biopsy: Achievement of over 99% Purity in Isolating Cancer DNA [Yahoo! Finance]
High
Report
Volition Reports Breakthrough in Liquid Biopsy: Achievement of over 99% Purity in Isolating Cancer DNA [Yahoo! Finance]
3/18
08:17 am
vnrx
Volition Reports Breakthrough in Liquid Biopsy: Achievement of over 99% Purity in Isolating Cancer DNA
Low
Report
Volition Reports Breakthrough in Liquid Biopsy: Achievement of over 99% Purity in Isolating Cancer DNA
3/6
08:10 am
vnrx
Volition Announces First Ever Automated Nu.Q® Vet Cancer Test with Fujifilm Vet Systems
Medium
Report
Volition Announces First Ever Automated Nu.Q® Vet Cancer Test with Fujifilm Vet Systems
2/25
08:39 am
vnrx
VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution [Yahoo! Finance]
High
Report
VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution [Yahoo! Finance]
2/25
08:10 am
vnrx
VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution
High
Report
VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution
2/10
08:07 am
vnrx
Volition Announces the Appointment of New Distributor for Nu.Q® Discover
High
Report
Volition Announces the Appointment of New Distributor for Nu.Q® Discover
2/9
05:20 pm
vnrx
VolitionRx Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
Low
Report
VolitionRx Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
2/4
08:45 am
vnrx
Volition Sponsors Symposium at 15th Conference of the European Hidradenitis Suppurativa Foundation
Low
Report
Volition Sponsors Symposium at 15th Conference of the European Hidradenitis Suppurativa Foundation
1/30
08:50 am
vnrx
VolitionRx Limited Announces the Preparation of Reimbursement Submission for its Nu.Q® Cancer Assays
Medium
Report
VolitionRx Limited Announces the Preparation of Reimbursement Submission for its Nu.Q® Cancer Assays
1/27
08:00 am
vnrx
Volition Announces Data to Support Use of Nu.Q® NETs in New Indication
Low
Report
Volition Announces Data to Support Use of Nu.Q® NETs in New Indication
1/21
08:00 am
vnrx
VolitionRx (NYSE:VNRX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $3.00 price target on the stock.
High
Report
VolitionRx (NYSE:VNRX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $3.00 price target on the stock.
1/20
08:25 am
vnrx
Volition Continues to Extend Access to Nu.Q® Vet Cancer Test
Low
Report
Volition Continues to Extend Access to Nu.Q® Vet Cancer Test
1/16
08:45 am
vnrx
Volition Sponsors Symposium at Veterinary Meeting and Expo
Medium
Report
Volition Sponsors Symposium at Veterinary Meeting and Expo
1/9
08:02 am
vnrx
VolitionRx (NYSE:VNRX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $3.00 price target on the stock.
Low
Report
VolitionRx (NYSE:VNRX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $3.00 price target on the stock.
1/8
09:23 am
vnrx
VolitionRx Announces Breakthrough Clinical Data for Nu.Q® Vet Cancer Test in Cats [Yahoo! Finance]
Low
Report
VolitionRx Announces Breakthrough Clinical Data for Nu.Q® Vet Cancer Test in Cats [Yahoo! Finance]
1/8
09:15 am
vnrx
VolitionRx Secures $2.0 Million in Funding
Medium
Report
VolitionRx Secures $2.0 Million in Funding
1/8
08:45 am
vnrx
VolitionRx Announces Breakthrough Clinical Data for Nu.Q® Vet Cancer Test in Cats
Medium
Report
VolitionRx Announces Breakthrough Clinical Data for Nu.Q® Vet Cancer Test in Cats